STAT Plus: Many drug companies working on Covid-19 vaccines and treatments are lobbying harder than usual
WASHINGTON — Pharmaceutical companies racing to develop coronavirus treatments and vaccines have upped their lobbying presence in the past three months, as drug companies work to combat the pandemic and fend off many lawmakers’ longstanding quest to lower drug prices via regulation.
Takeda, which is working to produce a plasma treatment for Covid-19, more than doubled its lobbying expenditure in the second quarter of 2020 compared to the same period a year ago: From $570,000 to $1.33 million.
